The purchase of the plant is to be finalized in the second quarter of 2026 and is consistent with the strategy of the Polish concern. Adamed plans to double its production volume by 2029 from the current level of 3.5 billion to 7 billion tablets per year. The transaction amount was not disclosed.
The plant in Riells, operating for over 50 years, produces approximately 75 million packages of medicines annually and employs over 200 employees. Its production goes to 77 countries around the world, but most of the exports are directed to European markets.
Adamed finalizes a large transaction
— We want to build on what is already there: people, their knowledge and experience. This is a solid bet that has a future ahead of it. This is a long-term project in which we intend to invest so that it will play an important role in the coming years – says Dr. Małgorzata Adamkiewicz, Chairwoman of the Supervisory Board of Adamed Pharma, about the transaction.
The rest of the article below the video:
Adamed has committed to maintaining the current employment level and working conditions. After a period of transitional co-management, scheduled to end in the second quarter of 2026, the company will take over full operational management of the plant. The company assures that production will be carried out without disruption to patients.
Going beyond the pattern
Adamed is implementing the transaction in parallel with the investment in Poland. The company currently has two production plants in Poland – in Pabianice and Ksawerów. It is also leading a project to expand the Production Center in Pabianice, and additionally plans to invest approximately PLN 300 million by 2030 in the construction of an inhaled medicines factory – a segment in which the growth prospects are particularly promising.
Over the last five years, Adamed has increased its drug production by 75%. — from 2 to 3.5 billion tablets per year. Paweł Roszczyk, Managing Director of Adamed Pharma, points to the geographical significance of the transaction. The company has been selling its products in Spain since 2009, and the transaction will strengthen its position in this market, which ranks second in Europe in terms of revenues.
“In large, international manufacturing companies, it is standard to become independent from one production site. Such diversification gives us greater flexibility and operational reliability. Spain is a strategic location for us, close to the Latin American markets where we want to strengthen our presence,” he says.
Polish aspiration on the European arena
The transaction also has a symbolic dimension – the Polish company is entering a market in which other large, international concerns already have an established position. Germany, France and the Benelux countries have held the position of pharmaceutical leaders for decades, Poland is far behind in this respect – although we are the 5th sales market in the EU, we are only 12th in terms of production.
Adamed is gradually breaking through on the global market. The Polish company's medicines reach patients in over 80 countries on 6 continents, and since 2017, the company also has a factory in Vietnam.
Sanofi's Director of Manufacturing and Supply Chain, Marzia Bove, emphasized the importance of the acquisition for continuity of supply. “The Riells plant plays an important role in providing medicines to patients around the world. We care about the long-term stability and development of production plants. We are convinced that under Adamed's management, the plant will maintain the highest quality and safety standards,” he says.
Grzegorz Kowalczyk, journalist of Business Insider Polska
